Dr. Nancy Reid
Purpose: The purpose of this article is to review the efficacy of immunotherapy in estrogen positive metastatic breast cancer.
Method: A PubMed literature search was conducted with search terms immunotherapy, chemotherapy and metastatic breast cancer. A filter was used to access articles with free full text that were written within the last five years. The most pertinent articles were selected for this clinical review.
Results: There is not enough research available to prove that estrogen positive metastatic breast cancer tumors respond significantly to immunotherapy. Checkpoint inhibitors, microsatellite instability high, mismatch-deficiency and tumor mutation burden levels are good predictors of response. Patients with those biomarkers may seek treatment when there are no other options.
Conclusion: Additional testing is needed to justify the use of immunotherapy in estrogen positive metastatic breast cancer.
Keywords: Immunotherapy, Metastatic Breast Cancer, Tumor Mutation Burden, Mismatch Repair, Checkpoint Inhibitor.
Target Audience. The target audience is physician assistants and nurse practitioners practicing in oncology.
Price, Letitia MCMSc, PA-C
"Is Immunotherapy An Effective Treatment Option For Estrogen Positive Metastatic Breast Cancer?,"
Lynchburg Journal of Medical Science: Vol. 2
, Article 32.
Available at: https://digitalshowcase.lynchburg.edu/dmscjournal/vol2/iss4/32
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.